Management of arterial hypertension with angiotensin receptor blockers: current evidence and the role of olmesartan.
No Thumbnail Available
Date
0000-00-00
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Elevated blood pressure BP is a major determinant of morbidity and mortality burden related to cardio metabolic risk Current guidelines indicate that controlling and lowering BP promotes cardiovascular CV risk reduction Among antihypertensive agents angiotensin receptor blockers ARBs are characterized by an efficacy profile equivalent to other antihypertensive agents and are provided with excellent tolerability profile and low discontinuation rates during chronic treatments Moreover CV outcomes are reduced by ARBs Olmesartan is a long lasting ARB which proved to achieve a comparable or more effective action in lowering BP when compared with other ARBs Olmesartan in fact displayed a larger and more sustained antihypertensive effect over the 24 hours with a buffering effect on short term BP variability These are important features which differentiate olmesartan from the other principles of the same class and that may help to control the increased CV risk in presence of high BP variability Olmesartan shows similar benefits as other ARBs in terms of all cause and CV mortality and a favourable tolerability profile Combination of olmesartan with long lasting calcium channel blockers and thiazide diuretics represents a rational and effective therapy Thus ARBs including olmesartan represent one of the most effective and safe treatment for patients with arterial hypertension This article is protected by copyright All rights reserved